/* */ PELVIPHARM - SPECIALIZED PRECLINICAL EXPERTISE in male and female sexual functions and diseases of the lower urinary tract
Receive our news

 
NEWS

May 5th - 2022

Presentations at the SEUD 2022


Pelvipharm will present oneabstracts during the session entitled "Basic science":
  • Rana Assaly  will present in poster session: "Establishment of a rodent model of endometriosis to evaluate the effect of new therapeutic strategies."
    S. Compagnie, M. Bracconi, P. Muthan, F. Giuliano, D. Behr-Roussel and R. Assaly.

Please come and see us, we will be happy to discuss our results with you and potential applications for you.

SEUD_vignette_2022.jpg

February 14th - 2022

Recently accepted paper in Toxins

BoNT/A1 Secondary Failure for the Treatment of Neurogenic Detrusor Overactivity: An Ex Vivo Functional Study

Jacquie Maignel, Vincent Martin, Rana Assaly, Mathieu L. Vogt, Kevin Retailleau, Alexandra Laugerotte, Stéphane Lezmi, Pierre Denys, Johannes Krupp and Charles Joussain

Toxins 2022, 14(2), 77

February 15th - 2022

Presentations at the Virtual ESSM 2022


Pelvipharm will present two abstracts during the session entitled "Basic science":
  • Rana Assaly  will present in video session: "Prolonged pro-erectile facilitator effect of LIB-01 in anesthetized Wistar rats."
    M. Razanakolona, C. Bradesi, M. Laurin, K. Fugl-Meyer, D. Behr-Roussel, F. Giuliano and R. Assaly
  • François Giuliano will present in video session: "Intracavernosal onabotulinumtoxinA exerts a synergistic pro-erectile effect when combined with sildenafil in spontaneously hypertensive rats"
    F. Giuliano, C. Joussain1, P. Denys, M. Laurin, D. Behr-Roussel and R. Assaly
  • François Giuliano will present in digital poster area: "Long term effectiveness and safety of intracavernosal botulinum toxin a as an add-on therapy tophosphosdiesterase type 5 inhibitors or prostaglandin e1 injections for erectile dysfunction – a case series study" (#169)
    F. Giuliano, C. Joussain, P. Denys 

 Please come and see us, we will be happy to discuss our results with you and potential applications for you. 

ESSM_2022_bis.jpeg

January 15th - 2022

Best Wishes 2022

Voeux_2022_Pelvipharm_taille_reduite.jpg

SITEMAP
TEL +331 704 293 39
FAX + 331 704 295 10
LEGAL